ADHD Drug Zenzedi Recalled Over Pill Mixup

2024-01-30
drugs
TUESDAY, Jan. 30, 2024 -- The maker of a drug used to treat ADHD and narcolepsy has recalled one lot of the medication after a pill mixup was discovered.
The recall notice, issued by Azurity Pharmaceuticals Inc., states that one lot of Zenzedi 30-milligram tablets is being recalled after a pharmacist found antihistamine tablets in a bottle labeled as Zenzedi.
The active compound in Zenzedi is dextroamphetamine sulfate, a stimulant used for the treatment of narcolepsy and ADHD. Meanwhile, the allergy drug found in the mislabeled bottles contains the sedative carbinoxamine, which has the opposite effect of a stimulant.
The recall comes amid an ongoing national shortage of ADHD drugs, creating further frustration for people with ADHD who have struggled to find medications for their condition, CNN reported.
The recall notice said that people who take carbinoxamine instead of Zenzedi have a higher risk of accidents or injuries and may have drowsiness, increased eye pressure, urinary obstruction and thyroid disorder. The recalled lot has the lot number F230169A and an expiration date of June 2025.
Azurity added that it has not received any reports of serious injury related to the medication mixup.
Consumers who have the recalled medication should return it to their pharmacy and call their doctor if they have any bad reactions to the drug.
Problems may also be reported to the FDA’s MedWatch Adverse Event Reporting program.
Sources
U.S. Food and Drug Administration, recall notice, Jan. 25, 2024
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Posted January 2024
More news resources
FDA Medwatch Drug Alerts
Daily MedNews
News for Health Professionals
New Drug Approvals
New Drug Applications
Drug Shortages
Clinical Trial Results
Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
机构
适应症
靶点
-
药物
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。